Description: Nemaura Medical, Inc. is a holding company. The Company owns a diagnostic medical device company specializing in discovering, developing and commercializing specialty medical devices. The Company's focus is on the development of a continuous glucose monitoring (CGM) device, which consists of a disposable patch containing a sensor, and a non-disposable miniature electronic watch with a re-chargeable power source. CGM through a non-invasive patch can enable early detection of subtle changes in blood glucose levels. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a CGM, named sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes, and may also be used to screen pre-diabetic patients. The sugarBEAT device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm.
Home Page: nemauramedical.com
NMRD Technical Analysis
57 West 57th Street
New York,
NY
10019
United States
Phone:
646 416 7912
Officers
| Name | Title |
|---|---|
| Dr. Dewan Fazlul Hoque Chowdhury Ph.D. | Chairman, CEO, Pres, Principal Financial Officer & Principal Accounting Officer |
| Dr. Arash Ghadar | Chief Operating Officer |
| Mr. Bashir Timol | Chief Bus. Officer & Director |
| Mr. Jay L. Warner | Head of U.S. Commercial Operations |
| Mr. Thomas Bendix Mortensen | Head of E.U. Commercial Operations & Marketing |
| Ms. Samantha Sanders | Global Head of Digital Programs |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Equipment & Supplies |
| GIC Sub-Industry: | Health Care Equipment |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 122.5612 |
| Price-to-Sales TTM: | 71.6132 |
| IPO Date: | 2016-03-04 |
| Fiscal Year End: | March |
| Full Time Employees: | 32 |